Fig. 5.

MDS and AML patients with low Stau1 level show inferior response to the DNMTi therapy. (A) Transient low-dose exposure of decitabine resulted in the induction of several ERV RNAs in KG-1 AML cells. n = 3 and error bars denote SEM. (B) Knockdown of Stau1 significantly rescued the cell death from decitabine treatment in KG-1 cells. n = 15 and error bars denote SEM. (C) Stau1 knockdown also resulted in decreased expression of several ERV RNAs examined. n = 3 and error bars denote SEM. (D) Analysis of dsRBP mRNA expression from RNAs isolated from bone marrow aspirates from 46 MDS and AML patients. All patients received the DNMTi therapy, and samples were grouped based on the treatment outcome. (E and F) Patients with low Stau1 expression exhibited poor PFS (E) and OS (F) compared to those with high Stau1 mRNA expression. (G) Examining the basal expression of several ERVs in bone marrow aspirates of MDS and AML patients before receiving the DNMTi treatment. Patients are subcategorized into good or poor groups based on their response to the treatment. *P value <0.05, **P value <0.01, ***P value <0.001, ****P value <0.0001.